Telix Class Action Seeks Losses After SEC Subpoena and FDA CRL Disclosures

Overview

• The filed lawsuit covers investors who bought Telix securities between Feb. 21 and Aug. 28, 2025.
• Complaints allege Telix overstated progress on prostate cancer candidates TLX591 and TLX592 and exaggerated the reliability of third‑party manufacturing partners.
• On July 22, 2025, Telix disclosed an SEC subpoena focused on its prostate therapeutics disclosures, and ADSs fell more than 13% over two sessions.
• On Aug. 28, 2025, Telix reported an FDA Complete Response Letter for TLX250‑CDx citing CMC deficiencies and Form 483 observations at two third‑party sites, and ADSs fell more than 21% over two sessions.
• Hagens Berman, Faruqi & Faruqi, Rosen Law Firm, and Berger Montague are soliciting class members, and notices state that no class has been certified.